<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336232">
  <stage>Registered</stage>
  <submitdate>15/11/2010</submitdate>
  <approvaldate>16/11/2010</approvaldate>
  <actrnumber>ACTRN12610000991011</actrnumber>
  <trial_identification>
    <studytitle>Dietary supplements and ocular (eye) comfort</studytitle>
    <scientifictitle>A randomised placebo-controlled double-masked study to investigate the effects of dietary supplementation with a combination of omega oils on ocular comfort including symptoms of dry eye</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>SOVS2010_BK001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Ocular comfort including symptoms of dry eye</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Normal eye development and function</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Other alternative and complementary medicine</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Dietary supplementation with a combination of omega oils. Dosage of  EPA (~550mg), DHA (~120mg) and a combination of liolenic acids per 3 capsules per day for 3 months</interventions>
    <comparator>Parrafin oil containing capsules. Dosage of three capsules per day for 3 months</comparator>
    <control>Placebo</control>
    <interventioncode>Other interventions</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Subjective ocular comfort assessed using validated questionnaires (OCI, OSDI, SESOD, numerical rating scales, WHS, DEQ)</outcome>
      <timepoint>Baseline, 1 month, 3-month</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Tear Film Stability, volume and composition assessed using NIBUT, osmometry, phenol red thread test</outcome>
      <timepoint>Baseline, 3-month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lipid layer thickness and meibum composition using tearscope, validated grading scales and spectrum analysis</outcome>
      <timepoint>Baseline, 3-month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cell and nerve morphology using impression cytology and confocal microscopy</outcome>
      <timepoint>Baseline, 3-month</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Willing to comply with the dosage and study visit schedule
Contact lens wearers and non contact lens wearers
At least 18 years old</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Current consumption of omega oil dietary supplements
Moderate or severe dry eye disease
Systematic disease that would preclude participants from safely ingesting dietary supplementation with omega oils
No S3 or above ocular medications
No use of any anticoagulants or blood thinning medications</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation to treatment is conducted following enrolment using numbered containers</concealment>
    <sequence>Randomisation will be stratified by contact lens wear. The manufacturer will code, bottle and label study supplies.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>15/11/2010</anticipatedstartdate>
    <actualstartdate>4/03/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>6/03/2012</actualenddate>
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2031</postcode>
    <postcode>2033</postcode>
    <postcode>2032</postcode>
    <postcode>2052</postcode>
    <postcode>2035</postcode>
    <postcode>2036</postcode>
    <postcode>2034</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Blackmores Limited</primarysponsorname>
    <primarysponsoraddress>20 Jubilee Avenue
Warriewood NSW 2021</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Blackmores Limited</fundingname>
      <fundingaddress>20 Jubilee Avenue
Warriewood NSW 2021</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of New South Wales</fundingname>
      <fundingaddress>School of Optometry and Vision Science
The Unviersity of New South Wales
UNSW Sydney NSW 2052</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of New South Wales</sponsorname>
      <sponsoraddress>School of Optometry and Vision Science
The Unviersity of New South Wales
UNSW Sydney NSW 2052</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to test whether omega oils taken as capsules can help in improving ocular comfort.</summary>
    <trialwebsite>http://www.optom.unsw.edu.au/news/2010/Researchrecruit.html</trialwebsite>
    <publication>1. Jalbert I, Gokhale M, Golebiowski B, Madigan M, Badarudin N, Garg M, Stapleton F. Effect of a combination omega dietary nutraceutical on symptoms of ocular discomfort, clinical indicators and biomarkers of ocular surface health. Optom Vis Sci 2013; 90: E-abstract 130891.
2. Golebiowski B, Hampel U, Badarudin N, Gokhale M, Jalbert I, Madigan M, Stapleton F. Is there a relationship between ocular discomfort and circulating plasma levels of sex hormones? Invest Ophthalmol Vis Sci 2013; 54: ARVO abstract 969.
3. Golebiowski B, Hampel U, Badarudin N, Gokhale M, Madigan M, Jalbert I, Stapleton F. Higher plasma levels of oestradiol are associated with increased ocular discomfort in women. 7th International Conference on the Tear Film &amp; Ocular Surface: Basic Science and Clinical Relevance, Taormina, Italy, September 2013.
4. Hampel U, Golebiowski B, Badarudin N, Jalbert I, Madigan MC, Stapleton F. Is there a relationship between ocular discomfort and circulating 3a-diol-G and DHEA-S serum levels in post-menopausal women? Stapleton F. Higher plasma levels of oestradiol are associated with increased ocular discomfort in women. 7th International Conference on the Tear Film &amp; Ocular Surface: Basic Science and Clinical Relevance, Taormina, Italy, September 2013.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Human Research Ethics Committee</ethicname>
      <ethicaddress>Grant Management Office
The University of New South Wales
UNSW Sydney NSW 2052</ethicaddress>
      <ethicapprovaldate>25/06/2010</ethicapprovaldate>
      <hrec>10110</hrec>
      <ethicsubmitdate>6/04/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Isabelle Jalbert</name>
      <address>School of Optometry and Vision Science
The University of New South Wales
Sydney NSW 2052</address>
      <phone>61-2-9385-9816</phone>
      <fax>61-2-9313-6243</fax>
      <email>i.jalbert@unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Isabelle Jalbert</name>
      <address>School of Optometry and Vision Science
The University of New South Wales
Sydney NSW 2052</address>
      <phone>61-2-9385-9816</phone>
      <fax>61-2-9313-6243</fax>
      <email>i.jalbert@unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Isabelle Jalbert</name>
      <address>School of Optometry and Vision Science
The University of New South Wales
Sydney NSW 2052</address>
      <phone>61-2-9385-9816</phone>
      <fax>61-2-9313-6243</fax>
      <email>i.jalbert@unsw.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Isabelle Jalbert</name>
      <address>School of Optometry and Vision Science
The University of New South Wales
Sydney NSW 2052</address>
      <phone>+61-2-9385-9816</phone>
      <fax />
      <email>i.jalbert@unsw.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>